MedTrace Logo

Phase I Study on Multiple Oral Dosing of CG100649

NCT01154790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-01-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of 3 escalating loading and maintenance dose regimens of CG100649 administered orally for 7 total days in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

CG100649

6 subjects: study drug 2 subjects: placebo

DRUG

Placebo

6 subjects: study drug 2 subjects: placebo

DRUG

Naproxen

6 subjects: study drug 2 subjects: placebo

Sponsors & Collaborators

  • CrystalGenomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Seonggu Ro · CrystalGenomics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154790 on ClinicalTrials.gov